KRONİK LENFOSİTİK LÖSEMİ TANILI HASTALARDA KİLLER İMMÜNOGLOBULİN LİKE RESEPTÖR GEN DÜZEYLERİ VE OTOİMMÜN OLAYLAR İLE İLİŞKİSİ

Amaç: İstanbul Üniversitesi Cerrahpaşa Tıp Fakültesi Hematoloji Polikliniği’nde takip edilen 49 Kronik Lenfositik Lösemi (KLL) hastası çalışmaya dahil edilmiştir. Çalışmanın amacı, çeşitli otoimmün hastalıklar ile ilişkisi gösterilmiş olan Killer Immunoglobuline Like Receptor (KIR) gen düzeylerini, otoimmün olay gözlenmiş ve gözlenmemiş KLL hasta grupları arasında karşılaştırmaktır. Gereç ve Yöntem: Bu doğrultuda otoimmün olay gözlenmiş olan 25 ve otoimmün olay gözlenmemiş 24 KLL hastası çalışmaya dahil edilmiştir. Hastaların 32’si erkek, 17’si kadındır. Otoimmün hastalık gözlenen grup ile otoimmün olay gözlenmeyen KLL grubu arasında tanı anındaki yaş (60 vs 64) ve ortanca takip süresi (59 ay vs 71 ay), tanı anındaki parametreleri istatistiki olarak benzerdir. Bulgular: Gözlenen en sık otoimmün olay otoimmün hemolitik anemi (OİHA) iken onu immün trombositopeni (İTP) ve saf eritroid aplazi (PRCA) takip etmiştir. Otoimmün olay gözlenmiş hastaların tanı anında direkt antiglobulin testi pozitiflik oranı, otoimmün olay gözlenmemiş KLL hastalarına göre artmış olduğu gözlenmiştir (p=0,024). Ayrıca otoimmün olay gözlenen hastaların tanı anında KLL hastalık evrelerinin daha ileri olduğu görülmüştür (p=0,04). Otoimmün olaylar kendi aralarında değerlendirildiğinde ise, sayı az olmasına karşın, PRCA’da çevresel kanda CD38 pozitif hücre oranının %30’un üstünde olma sıklığının arttığı gözlenmiştir (p=0,008). Sonuç: Çalışmamızda KIR genlerinin otoimmün olaylarla ilişkisi incelendiğinde, otoimmünite gözlenmeyen gruba göre herhangi bir istatistiki fark tespit edilememiştir. Daha iyi teknik şartlarda yeni çalışmalar yapılmasında fayda vardır.

KILLER IMMUNOGLOBULINE LIKE RECEPTOR GENE ANALYSIS IN CHRONIC LYMPHOCYTIC LEUKEMIA AND ITS RELATION WITH AUTOIMMUNITY

Objective: Our study was performed on 49 chronic lymphocytic leukemia (CLL) patients followed in the outpatient clinic of the Istanbul University Cerrahpasa Medical Faculty Department of Hematology. We aimed to analyze the relationship between autoimmune phenomena and CLL. Methods: Twenty-five CLL patients with and 24 CLL patients without autoimmune phenomenon were included. Thirty-two of them were male and 17 were female. No statistically significant difference in the median age at diagnosis (60 vs 64) and in the median follow-up time (59 months vs 71 months) was detected. The initial diagnostic parameters were similar. Results: In our autoimmune phenomenon cohort, the most frequent autoimmune disease was autoimmune hemolytic anemia (AIHA) followed by immune thrombocytopenia (ITP) and pure red cell aplasia (PRCA). The direct antiglobulin positivity at the time of diagnosis was increased in the autoimmune phenomenon group (p=0.024). Additionally, the stage of CLL in patients of the autoimmune phenomenon group was more advanced than the other group (p=0.04). Although the number of autoimmune phenomena was not high enough, the CD38 positive cell ratio over 30% in the peripheral blood was more frequent in PRCA group (p=0.008). Conclusion: We could not determine a relationship between autoimmunity in CLL and KIR genotypes. We believe that a new study in a larger cohort with superior technical conditions should be planned to find accurate responses to our study.

Kaynakça

1. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111(12):5446-56. [CrossRef]

2. Hamblin TJ, Orchard JA, Ibbotson RE, Davis Z, Thomas PW, Stevenson FK, et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 2002;99(3):1023-9. [CrossRef]

3. Hamblin TJ. Autoimmune complications of chronic lymphocytic leukemia. Semin Oncol 2006;33(2):230-9. [CrossRef]

4. Hodgson K, Ferrer G, Montserrat E, Moreno C. Chronic lymphocytic leukemia and autoimmunity: a systematic review. Haematologica 2011;96(5):752-61. [CrossRef]

5. Ghia P, Guida G, Stella S, Gottardi D, Geuna M, Strola G, et al. The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. Blood 2003;101(4):1262-9. [CrossRef]

6. Hodgson K, Ferrer G, Pereira A, Moreno C, Montserrat E. Autoimmune cytopenia in chronic lymphocytic leukaemia: diagnosis and treatment. Br J Haematol 2011;154(1):14-22. [CrossRef]

7. Akpinar S. Kronik Lenfositik Lösemide KIR gen polimorfizmi [Yandal Uzmanlık Tezi]. Edirne: Trakya Üniversitesi Tıp Fakültesi; 2013.

8. Campbell KS, Purdy AK. Structure/function of human killer cell immunoglobulin-like receptors: lessons from polymorphisms, evolution, crystal structures and mutations. Immunology 2011;132(3):315-25. [CrossRef]

9. Purdy AK, Campbell KS. Natural killer cells and cancer: regulation by the killer cell Ig-like receptors (KIR). Cancer Biol Ther 2009;8(23):2211-20. [CrossRef]

10. Nourse JP, Lea R, Crooks P, Wright G, Tran H, Catalano J, et al. The KIR2DS2/DL2 genotype is associated with adult persistent/chronic and relapsed immune thrombocytopenia independently of FCGR3a-158 polymorphisms. Blood Coagul Fibrinolysis 2012;23(1):45-50. [CrossRef]

11. Shastry A, Sedimbi SK, Rajalingam R, Rumba I, Kanungo A, Sanjeevi CB. Different KIRs confer susceptibility and protection to adults with latent autoimmune diabetes in Latvian and Asian Indian populations. Ann N Y Acad Sci 2008;1150:133-8. [CrossRef]

12. Salim PH, Jobim M, Jobim LF, Xavier RM. Autoimmune rheumatic diseases and their association with killer immunoglobulin-like receptor genes. Rev Bras Reumatol. 2011;51(4):351-6, 62-4. doi: S0482-50042011000400007

13. Karabon L, Jedynak A, Giebel S, Wolowiec D, Kielbinski M, Woszczyk D, et al. KIR/HLA gene combinations influence susceptibility to B-cell chronic lymphocytic leukemia and the clinical course of disease. Tissue Antigens 2011;78(2):129- 38. [CrossRef]

14. Junevik K, Werlenius O, Hasselblom S, Jacobsson S, Nilsson- Ehle H, Andersson PO. The expression of NK cell inhibitory receptors on cytotoxic T cells in B-cell chronic lymphocytic leukaemia (B-CLL). Ann Hematol 2007;86(2):89-94. [CrossRef]

15. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood 1975;46(2):219-34. [CrossRef]

16. Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981;48(1):198-206. [CrossRef]

17. Olerup. KIR genotyping [11.07.2015]. Available from: http:// www.olerup-ssp.com/productfiles/interpretation_tables/ KIR%20Genotyping%202013%2078R%20R01.pdf.

18. Bastion Y, Coiffier B, Dumontet C, Espinouse D, Bryon PA. Severe autoimmune hemolytic anemia in two patients treated with fludarabine for chronic lymphocytic leukemia. Ann Oncol 1992;3(2):171-2. [CrossRef]

19. Tosti S, Caruso R, D’Adamo F, Picardi A, Ali Ege M, Girelli G, et al. Severe autoimmune hemolytic anemia in a patient with chronic lymphocytic leukemia responsive to fludarabinebased treatment. Ann Hematol 1992;65(5):238-9. [CrossRef]

20. Myint H, Copplestone JA, Orchard J, Craig V, Curtis D, Prentice AG, et al. Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia. Br J Haematol 1995;91(2):341-4. [CrossRef]

21. Wing K, Sakaguchi S. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol 2010;11(1):7-13. [CrossRef]

22. Borthakur G, O’Brien S, Wierda WG, Thomas DA, Cortes JE, Giles FJ, et al. Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors. Br J Haematol 2007;136(6):800-5. [CrossRef]

23. Dearden C, Wade R, Else M, Richards S, Milligan D, Hamblin T, et al. The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia. Blood 2008;111(4):1820-6. [CrossRef]

24. Hamblin TJ, Oscier DG, Young BJ. Autoimmunity in chronic lymphocytic leukaemia. J Clin Pathol 1986;39(7):713-6. [CrossRef]

25. Zent CS, Ding W, Schwager SM, Reinalda MS, Hoyer JD, Jelinek DF, et al. The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma. Br J Haematol 2008;141(5):615-21. [CrossRef]

26. Barcellini W, Capalbo S, Agostinelli RM, Mauro FR, Ambrosetti A, Calori R, et al. Relationship between autoimmune phenomena and disease stage and therapy in B-cell chronic lymphocytic leukemia. Haematologica 2006;91(12):1689-92.

27. Mauro FR, Foa R, Cerretti R, Giannarelli D, Coluzzi S, Mandelli F, et al. Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features. Blood 2000;95(9):2786-92. [CrossRef]

28. Moreno C, Hodgson K, Ferrer G, Elena M, Filella X, Pereira A, et al. Autoimmune cytopenia in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance. Blood 2010;116(23):4771-6. [CrossRef]

29. Visco C, Ruggeri M, Laura Evangelista M, Stasi R, Zanotti R, Giaretta I, et al. Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia. Blood 2008;111(3):1110-6. [CrossRef]

30. Hall AM, Vickers MA, McLeod E, Barker RN. Rh autoantigen presentation to helper T cells in chronic lymphocytic leukemia by malignant B cells. Blood 2005;105(5):2007-15. [CrossRef]

31. Galletti J, Canones C, Morande P, Borge M, Oppezzo P, Geffner J, et al. Chronic lymphocytic leukemia cells bind and present the erythrocyte protein band 3: possible role as initiators of autoimmune hemolytic anemia. J Immunol. 2008;181(5):3674-83. [CrossRef]

32. von Bergwelt-Baildon M, Maecker B, Schultze J, Gribben JG. CD40 activation: potential for specific immunotherapy in B-CLL. Ann Oncol 2004;15(6):853-7. [CrossRef]

33. Dreger P, Ghia P, Schetelig J, van Gelder M, Kimby E, Michallet M, et al. High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies. Blood 2018;132(9):892-902. [CrossRef]

34. Bachanova V, Weisdorf DJ, Wang T, Marsh SGE, Cereb N, Haagenson MD, et al. Donor Killer Cell Immunoglobulin- Like Receptor Genotype Does Not Improve Graft-versus- Leukemia Responses in Chronic Lymphocytic Leukemia after Unrelated Donor Transplant: A Center for International Blood and Marrow Transplant Research Analysis. Biol Blood Marrow Transplant 2019;25(5):949-54. doi: 10.1016/j. bbmt.2018.12.763. [CrossRef]

35. Williams F, Meenagh A, Sleator C, Cook D, Fernandez-Vina M, Bowcock AM, et al. Activating killer cell immunoglobulinlike receptor gene KIR2DS1 is associated with psoriatic arthritis. Hum Immunol 2005;66(7):836-41. [CrossRef]

36. Romero V, Zuniga J, Azocar J, Clavijo OP, Terreros D, Kidwai H, et al. Genetic interactions of KIR and G1M immunoglobulin allotypes differ in obese from nonobese individuals with type 2 diabetes. Mol Immunol. 2008;45(14):3857-62. [CrossRef]

37. Pellett F, Siannis F, Vukin I, Lee P, Urowitz MB, Gladman DD. KIRs and autoimmune disease: studies in systemic lupus erythematosus and scleroderma. Tissue Antigens 2007;69 Suppl 1:106-8. [CrossRef]

38. Lowe DP, Cook MA, Bowman SJ, Briggs DC. Association of killer cell immunoglobulin-like receptors with primary Sjogren’s syndrome. Rheumatology (Oxford) 2009;48(4):359- 62. [CrossRef]

39. Jiao YL, Zhang BC, You L, Li JF, Zhang J, Ma CY, et al. Polymorphisms of KIR gene and HLA-C alleles: possible association with susceptibility to HLA-B27-positive patients with ankylosing spondylitis. J Clin Immunol 2010;30(6):840- 4. [CrossRef]

40. Fusco C, Guerini FR, Nocera G, Ventrella G, Caputo D, Valentino MA, et al. KIRs and their HLA ligands in remittingrelapsing multiple sclerosis. J Neuroimmunol 2010;229(1- 2):232-7. [CrossRef]

41. Cosentini E, Gargiulo L, Bruno P, Lastraioli S, Risitano A, Camerlingo R, et al. Killer immunoglobulin-like receptors (KIR) and their HLA-ligands in Italian paroxysmal nocturnal haemoglobinuria (PNH) patients. Tissue Antigens 2012;80(4):322-7. [CrossRef]

42. Taintor AR, Leiferman KM, Hashimoto T, Ishii N, Zone JJ, Hull CM. A novel case of IgA paraneoplastic pemphigus associated with chronic lymphocytic leukemia. J Am Acad Dermatol 2007;56(5 Suppl):S73-6. [CrossRef]

43. Seymour LA, Nourse JP, Crooks P, Wockner L, Bird R, Tran H, et al. The presence of KIR2DS5 confers protection against adult immune thrombocytopenia. Tissue Antigens. 2014;83(3):154-60. [CrossRef]

Kaynak Göster

Bibtex @araştırma makalesi { iuitfd931662, journal = {Journal of Istanbul Faculty of Medicine}, issn = {}, eissn = {1305-6441}, address = {}, publisher = {İstanbul Üniversitesi}, year = {2021}, volume = {84}, pages = {227 - 236}, doi = {10.26650/IUITFD.2020.0037}, title = {KRONİK LENFOSİTİK LÖSEMİ TANILI HASTALARDA KİLLER İMMÜNOGLOBULİN LİKE RESEPTÖR GEN DÜZEYLERİ VE OTOİMMÜN OLAYLAR İLE İLİŞKİSİ}, key = {cite}, author = {Özbalak, Murat and Erdoğan Özünal, Işıl and Berk, Selin and Elverdi, Tuğrul and Salihoğlu, Ayşe and Eşkazan, Ahmet Emre and Özbalak, Ezgi Pınar and Ar, Cem and Öngören, Şeniz and Başlar, Zafer and Aydın, Yıldız and Ekizoğlu, Seda and Çelebi, Asuman and Buyru, Ayşe Nur and Soysal, Teoman} }
APA Özbalak, M , Erdoğan Özünal, I , Berk, S , Elverdi, T , Salihoğlu, A , Eşkazan, A , Özbalak, E , Ar, C , Öngören, Ş , Başlar, Z , Aydın, Y , Ekizoğlu, S , Çelebi, A , Buyru, A , Soysal, T . (2021). KRONİK LENFOSİTİK LÖSEMİ TANILI HASTALARDA KİLLER İMMÜNOGLOBULİN LİKE RESEPTÖR GEN DÜZEYLERİ VE OTOİMMÜN OLAYLAR İLE İLİŞKİSİ . Journal of Istanbul Faculty of Medicine , 84 (2) , 227-236 . DOI: 10.26650/IUITFD.2020.0037
MLA Özbalak, M , Erdoğan Özünal, I , Berk, S , Elverdi, T , Salihoğlu, A , Eşkazan, A , Özbalak, E , Ar, C , Öngören, Ş , Başlar, Z , Aydın, Y , Ekizoğlu, S , Çelebi, A , Buyru, A , Soysal, T . "KRONİK LENFOSİTİK LÖSEMİ TANILI HASTALARDA KİLLER İMMÜNOGLOBULİN LİKE RESEPTÖR GEN DÜZEYLERİ VE OTOİMMÜN OLAYLAR İLE İLİŞKİSİ" . Journal of Istanbul Faculty of Medicine 84 (2021 ): 227-236 <https://dergipark.org.tr/tr/pub/iuitfd/issue/62206/931662>
Chicago Özbalak, M , Erdoğan Özünal, I , Berk, S , Elverdi, T , Salihoğlu, A , Eşkazan, A , Özbalak, E , Ar, C , Öngören, Ş , Başlar, Z , Aydın, Y , Ekizoğlu, S , Çelebi, A , Buyru, A , Soysal, T . "KRONİK LENFOSİTİK LÖSEMİ TANILI HASTALARDA KİLLER İMMÜNOGLOBULİN LİKE RESEPTÖR GEN DÜZEYLERİ VE OTOİMMÜN OLAYLAR İLE İLİŞKİSİ". Journal of Istanbul Faculty of Medicine 84 (2021 ): 227-236
RIS TY - JOUR T1 - KRONİK LENFOSİTİK LÖSEMİ TANILI HASTALARDA KİLLER İMMÜNOGLOBULİN LİKE RESEPTÖR GEN DÜZEYLERİ VE OTOİMMÜN OLAYLAR İLE İLİŞKİSİ AU - Murat Özbalak , Işıl Erdoğan Özünal , Selin Berk , Tuğrul Elverdi , Ayşe Salihoğlu , Ahmet Emre Eşkazan , Ezgi Pınar Özbalak , Cem Ar , Şeniz Öngören , Zafer Başlar , Yıldız Aydın , Seda Ekizoğlu , Asuman Çelebi , Ayşe Nur Buyru , Teoman Soysal Y1 - 2021 PY - 2021 N1 - doi: 10.26650/IUITFD.2020.0037 DO - 10.26650/IUITFD.2020.0037 T2 - Journal of Istanbul Faculty of Medicine JF - Journal JO - JOR SP - 227 EP - 236 VL - 84 IS - 2 SN - -1305-6441 M3 - doi: 10.26650/IUITFD.2020.0037 UR - https://doi.org/10.26650/IUITFD.2020.0037 Y2 - 2021 ER -
EndNote %0 İstanbul Tıp Fakültesi Dergisi KRONİK LENFOSİTİK LÖSEMİ TANILI HASTALARDA KİLLER İMMÜNOGLOBULİN LİKE RESEPTÖR GEN DÜZEYLERİ VE OTOİMMÜN OLAYLAR İLE İLİŞKİSİ %A Murat Özbalak , Işıl Erdoğan Özünal , Selin Berk , Tuğrul Elverdi , Ayşe Salihoğlu , Ahmet Emre Eşkazan , Ezgi Pınar Özbalak , Cem Ar , Şeniz Öngören , Zafer Başlar , Yıldız Aydın , Seda Ekizoğlu , Asuman Çelebi , Ayşe Nur Buyru , Teoman Soysal %T KRONİK LENFOSİTİK LÖSEMİ TANILI HASTALARDA KİLLER İMMÜNOGLOBULİN LİKE RESEPTÖR GEN DÜZEYLERİ VE OTOİMMÜN OLAYLAR İLE İLİŞKİSİ %D 2021 %J Journal of Istanbul Faculty of Medicine %P -1305-6441 %V 84 %N 2 %R doi: 10.26650/IUITFD.2020.0037 %U 10.26650/IUITFD.2020.0037
ISNAD Özbalak, Murat , Erdoğan Özünal, Işıl , Berk, Selin , Elverdi, Tuğrul , Salihoğlu, Ayşe , Eşkazan, Ahmet Emre , Özbalak, Ezgi Pınar , Ar, Cem , Öngören, Şeniz , Başlar, Zafer , Aydın, Yıldız , Ekizoğlu, Seda , Çelebi, Asuman , Buyru, Ayşe Nur , Soysal, Teoman . "KRONİK LENFOSİTİK LÖSEMİ TANILI HASTALARDA KİLLER İMMÜNOGLOBULİN LİKE RESEPTÖR GEN DÜZEYLERİ VE OTOİMMÜN OLAYLAR İLE İLİŞKİSİ". Journal of Istanbul Faculty of Medicine 84 / 2 (Nisan 2021): 227-236 . https://doi.org/10.26650/IUITFD.2020.0037
AMA Özbalak M , Erdoğan Özünal I , Berk S , Elverdi T , Salihoğlu A , Eşkazan A , Özbalak E , Ar C , Öngören Ş , Başlar Z , Aydın Y , Ekizoğlu S , Çelebi A , Buyru A , Soysal T . KRONİK LENFOSİTİK LÖSEMİ TANILI HASTALARDA KİLLER İMMÜNOGLOBULİN LİKE RESEPTÖR GEN DÜZEYLERİ VE OTOİMMÜN OLAYLAR İLE İLİŞKİSİ. İst Tıp Fak Derg. 2021; 84(2): 227-236.
Vancouver Özbalak M , Erdoğan Özünal I , Berk S , Elverdi T , Salihoğlu A , Eşkazan A , Özbalak E , Ar C , Öngören Ş , Başlar Z , Aydın Y , Ekizoğlu S , Çelebi A , Buyru A , Soysal T . KRONİK LENFOSİTİK LÖSEMİ TANILI HASTALARDA KİLLER İMMÜNOGLOBULİN LİKE RESEPTÖR GEN DÜZEYLERİ VE OTOİMMÜN OLAYLAR İLE İLİŞKİSİ. Journal of Istanbul Faculty of Medicine. 2021; 84(2): 227-236.
IEEE M. Özbalak , I. Erdoğan Özünal , S. Berk , T. Elverdi , A. Salihoğlu , A. Eşkazan , E. Özbalak , C. Ar , Ş. Öngören , Z. Başlar , Y. Aydın , S. Ekizoğlu , A. Çelebi , A. Buyru ve T. Soysal , "KRONİK LENFOSİTİK LÖSEMİ TANILI HASTALARDA KİLLER İMMÜNOGLOBULİN LİKE RESEPTÖR GEN DÜZEYLERİ VE OTOİMMÜN OLAYLAR İLE İLİŞKİSİ", Journal of Istanbul Faculty of Medicine, c. 84, sayı. 2, ss. 227-236, Nis. 2021, doi:10.26650/IUITFD.2020.0037

29000 16151

Arşiv
Sayıdaki Diğer Makaleler

DEPRESYON VE KİŞİLİK DEĞİŞİKLİLERİ İLE ORTAYA ÇIKAN GLİOBLASTOMA: BİR OLGU SUNUMU

Yaşar KAPICI, Olga BAYAR KAPICI, Aslı EGELİ, Atilla TEKİN

VULVAR HİDRADENOMA PAPİLLİFERUM: OLGU SUNUMU

Ayhan ATIGAN, Derya KILIÇ, Yeliz ARMAN KARAKAYA, Ömer Tolga GÜLER

HEMATOLOJİK KANSER TANISI ALAN BİREYLERDE DİSTRES VE ALEKSİTİMİNİN İNCELENMESİ

Didem AYHAN, Neşe MERCAN, Reyhan DOĞAN, Çiğdem YÜKSEK

COVID-19’DA İMMÜN YANITLAR

Bülent ÇAKAL

VARİS KANAMASI OLAN SİROZ HASTALARINDA QTC İNTERVALİNİN DEĞERLENDİRİLMESİ

Rezan KARAALİ, Umut PAYZA, Ahmet KAYALI, Firdevs TOPAL, Fatih Esad TOPAL

KRONİK LENFOSİTİK LÖSEMİ TANILI HASTALARDA KİLLER İMMÜNOGLOBULİN LİKE RESEPTÖR GEN DÜZEYLERİ VE OTOİMMÜN OLAYLAR İLE İLİŞKİSİ

Murat ÖZBALAK, Işıl ERDOĞAN ÖZÜNAL, Selin BERK, Tuğrul ELVERDİ, Ayşe SALİHOĞLU, Ahmet Emre EŞKAZAN, Ezgi Pınar ÖZBALAK, Cem AR, Şeniz ÖNGÖREN, Zafer BAŞLAR, Yıldız AYDIN, Seda EKİZOĞLU, Asuman ÇELEBİ, Ayşe Nur BUYRU, Teoman SOYSAL

DOĞUM VE PELVİK TABAN DİSFONKSİYONU

Nezihe KIZILKAYA BEJİ, Elif Zahide ÇELEBİ, Nilgün AVCI

OLGU SUNUMU: AZİTROMİSİN PROVOKASYONU ESNASINDA ANAFİLAKSİ

Ayşe SÜLEYMAN, Esra ÖZEK YÜCEL, Sevgi SİPAHİ ÇİMEN, Zeynep HIZLI DEMİRKALE, Cevdet ÖZDEMİR, Zeynep Ülker TAMAY, Nermin GÜLER

IN VIVO MODELDE YARIK DAMAK CERRAHİSİNDE N-BUTİL-2-SİYANOAKRİLATIN KULLANIMI VE ETKİNLİĞİNİN SÜTÜR MATERYALİ İLE KARŞILAŞTIRILMASI

Furkan KARABULUT, Serhat ÖZBEK

KRONİK BÖBREK HASTALIĞINDA ARTERİYEL SERTLİĞİN BÖBREK PROGRESYONU VE MORTALİTE ÜZERİNE ETKİSİ

Edip ERKUŞ, Süleyman KARAKÖSE, Pervin ÖZKAN KURTGÖZ, Vedat GENÇER, İbrahim GÜNEY